Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 51 to 60 of 400 total matches.

Relyvrio for ALS

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
® Vol. 64 (1664) November 28, 2022 of room-temperature water and administered before a snack or meal ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose combination of sodium phenylbutyrate and taurursodiol, for treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate (Buphenyl, and others) has been available by prescription for years for treatment of urea cycle disorders. Taurursodiol (tauroursodeoxycholic acid), a derivative of ursodiol, is an over-the-counter bile acid supplement claimed to have neuroprotective benefits. Relyvrio is the third drug to be approved in the US for treatment of ALS; riluzole (Rilutek, and others) and edaravone (Radicava, Radicava...
Med Lett Drugs Ther. 2022 Nov 28;64(1664):190-1 |  Show IntroductionHide Introduction

Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
%). Severe The Medical Letter ® Vol. 65 (1667) January 9, 2023 8 lymphopenia lasting ≥1 week occurred ...
Teplizumab-mzwv (Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old who have stage 2 type 1 diabetes. It is the first drug to become available in the US that delays the onset of type 1 diabetes.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):7-8   doi:10.58347/tml.2023.1667c |  Show IntroductionHide Introduction

Transdermal Dextroamphetamine (Xelstrym) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023  (Issue 1669)
. The Medical Letter ® Vol. 65 (1669) February 6, 2023 23 Use of CNS stimulants in children is associated ...
The FDA has approved a dextroamphetamine transdermal patch (Xelstrym – Noven) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Xelstrym is the first transdermal amphetamine product to be approved in the US. A methylphenidate transdermal patch (Daytrana, and generics) has been available for years for treatment of ADHD.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):22-4   doi:10.58347/tml.2023.1669d |  Show IntroductionHide Introduction

Antiviral Drugs for COVID-19 in Vaccinated Outpatients

   
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023  (Issue 1671)
® Vol. 65 (1671) March 6, 2023 34 had previously received ≥3 COVID-19 vaccine doses ...
Three products are currently available in the US for treatment of high-risk,1 nonhospitalized adults with mild to moderate COVID-19: oral ritonavir-boosted nirmatrelvir (Paxlovid), IV remdesivir (Veklury), and oral molnupiravir (Lagevrio). Remdesivir is FDA-approved for such use; nirmatrelvir/ritonavir and molnupiravir are available under an FDA Emergency Use Authorization. Because the pivotal clinical trials of these products for outpatient use were conducted in patients who were not vaccinated against COVID-19, some clinicians have questioned whether they can benefit vaccinated...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):33-4   doi:10.58347/tml.2023.1671a |  Show IntroductionHide Introduction

Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023  (Issue 1671)
® Vol. 65 (1671) March 6, 2023 39 impairment (Child-Pugh B); the drug should not be used in patients ...
The FDA has approved elacestrant (Orserdu – Stemline), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in postmenopausal women or men who had disease progression following endocrine therapy. Elacestrant is the first oral selective estrogen receptor degrader (SERD) to be approved for treatment of breast cancer; the injectable SERD fulvestrant (Faslodex, and generics) was approved more than 20 years...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):38-40   doi:10.58347/tml.2023.1671d |  Show IntroductionHide Introduction

Lenacapavir (Sunlenca) for Multidrug-Resistant HIV

   
The Medical Letter on Drugs and Therapeutics • May 01, 2023  (Issue 1675)
/drugpricing- policy. The Medical Letter ® Vol. 65 (1675) May 1, 2023 69 ADVERSE EFFECTS – Injection-site ...
The FDA has approved oral and injectable formulations of the HIV-1 capsid inhibitor lenacapavir (Sunlenca – Gilead) for use with other antiretroviral drugs to treat multidrug-resistant HIV-1 infection (MDR-HIV) in heavily treatment-experienced adults whose current regimen is failing. Lenacapavir is the third drug to be approved exclusively for treatment of MDR-HIV; the intravenously administered CD4-directed antibody ibalizumab-uiyk (Trogarzo) and the orally administered HIV-1 gp120-directed attachment inhibitor fostemsavir (Rukobia) were approved earlier.
Med Lett Drugs Ther. 2023 May 1;65(1675):68-70   doi:10.58347/tml.2023.1675c |  Show IntroductionHide Introduction

Etrasimod (Velsipity) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023  (Issue 1690)
. The Medical Letter® Vol. 65 (1690) November 27, 2023 Key Points: Etrasimod (Velsipity) Description ...
The oral sphingosine 1-phosphate (S1P) receptor modulator etrasimod (Velsipity – Pfizer) has been approved by the FDA for treatment of moderately to severely active ulcerative colitis in adults. It is the second oral S1P receptor modulator to be approved in the US for this indication; ozanimod (Zeposia) was the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9   doi:10.58347/tml.2023.1690b |  Show IntroductionHide Introduction

IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
no dose no dose 1. For iron deficiency in adults with heart failure. The Medical Letter ® Vol. 66 (1695 ...
Ferric carboxymaltose (Injectafer – American Regent) is now FDA-approved for IV treatment of iron deficiency in adults with New York Heart Association (NYHA) class II/III heart failure to improve exercise capacity. Iron deficiency is present in approximately 30% of patients with heart failure; it has been associated with reduced quality of life and increased hospitalization and mortality. Injectafer is the first IV iron preparation to be approved for this indication. It was previously approved for treatment of iron deficiency anemia in children and adults.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):22-4   doi:10.58347/tml.2024.1695d |  Show IntroductionHide Introduction

Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024  (Issue 1697)
%) The Medical Letter ® Vol. 66 (1697) March 4, 2024 39 1. Tenapanor (Ibsrela) for irritable bowel syndrome ...
The FDA has approved the sodium/hydrogen exchanger 3 (NHE3) inhibitor tenapanor (Xphozah – Ardelyx) to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy when phosphate binders are ineffective or as monotherapy when phosphate binders cannot be tolerated. Tenapanor is the first NHE3 inhibitor to be approved in the US for hyperphosphatemia. It was previously approved as Ibsrela to treat irritable bowel syndrome with constipation (IBS-C).
Med Lett Drugs Ther. 2024 Mar 4;66(1697):38-9   doi:10.58347/tml.2024.1697b |  Show IntroductionHide Introduction

Mirikizumab (Omvoh) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024  (Issue 1698)
with ulcerative colitis) The Medical Letter ® Vol. 66 (1698) March 18, 2024 47 In LUCENT II, 544 patients who ...
The FDA has approved the interleukin (IL)-23 antagonist mirikizumab-mrkz (Omvoh – Lilly) for treatment of moderately to severely active ulcerative colitis (UC) in adults. Mirikizumab is the first selective IL-23 antagonist to be approved for this indication. Ustekinumab (Stelara), an IL-12/23 antagonist, was approved for treatment of UC in 2019. The IL-23 antagonist risankizumab (Skyrizi) is approved for treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7   doi:10.58347/tml.2024.1698c |  Show IntroductionHide Introduction